Literature DB >> 31955417

MID3: Mission Impossible or Model-Informed Drug Discovery and Development? Point-Counterpoint Discussions on Key Challenges.

Sriram Krishnaswami1, Daren Austin2, Oscar Della Pasqua3, Marc R Gastonguay4, Jogarao Gobburu5, Piet H van der Graaf6, Daniele Ouellet7, Stacey Tannenbaum8, Sandra A G Visser9.   

Abstract

Entities:  

Year:  2020        PMID： 31955417     DOI： 10.1002/cpt.1788

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  4 in total

Review 1.  End-to-end application of model-informed drug development for ertugliflozin, a novel sodium-glucose cotransporter 2 inhibitor.

Authors:  Daryl J Fediuk; Gianluca Nucci; Vikas K Dawra; Ernesto Callegari; Susan Zhou; Cynthia J Musante; Yali Liang; Kevin Sweeney; Vaishali Sahasrabudhe
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-05-15

Review 2.  Model-Informed Drug Development for Anti-Infectives: State of the Art and Future.

Authors:  Craig R Rayner; Patrick F Smith; David Andes; Kayla Andrews; Hartmut Derendorf; Lena E Friberg; Debra Hanna; Alex Lepak; Edward Mills; Thomas M Polasek; Jason A Roberts; Virna Schuck; Mark J Shelton; David Wesche; Karen Rowland-Yeo
Journal:  Clin Pharmacol Ther       Date:  2021-03-09       Impact factor: 6.875

3.  Perspective on model-informed drug development.

Authors:  Lawrence J Lesko
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-08-17

Review 4.  Sagacious epitope selection for vaccines, and both antibody-based therapeutics and diagnostics: tips from virology and oncology.

Authors:  Samuel Ken-En Gan; Ser-Xian Phua; Joshua Yi Yeo
Journal:  Antib Ther       Date:  2022-02-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.